News

Bayer's Kerendia gains FDA approval for CKD linked to type 1 diabetes, expanding its patient reach and growth prospects.

FDA clearance for Abbott’s TactiFlex Duo follows the dual ablation catheter’s receipt of a European CE mark in January 2026.

Fox (FOX) is facing expanded antitrust scrutiny from the US Department of Justice over its $22 billi

Gilead Sciences is branching out beyond its HIV franchise into oncology and immunology therapies.

Alphabet stock soared the last time a judge rejected the Justice Department's bid to force it to sell part of its business.

Citi said continued advertiser spending and accelerating AI demand at AWS support its bullish view of Amazon.

Eli Lilly stock has delivered very strong gains over the past five years. Current checks give a mixed read on valuation, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to upside, while market based multiples look closer to fair. Eli Lilly has returned 373.6% over five years, which puts a lot of optimism into the share price and raises the bar for what counts as good value today. The expanded use of drugs like Mounjaro and Zepbound in metabolic and cardiovascular care...

The chip giant stepped back from the AI Compute Partnership program last week, less than two months after announcing it in July

The company is changing how it enforces its site reputation policy within the European Economic Area, to appease regulators and avoid a potentially hefty fine.

The U.S. Food and Drug Administration (FDA) on Tuesday approved Abbott Laboratories’ Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged two and older. The regulatory nod makes the device the first wearable in the...

The U.S. FDA has approved Bristol-Myers Squibb Company (NYSE:BMY)’s oral blood-cancer drug iberdomide, sold as Zenbexus, for patients with relapsed or refractory multiple myeloma. The treatment is given with Johnson & Johnson’s Darzalex and dexamethasone. The approval gives BMY another product that could support growth in its oncology business. Iberdomide belongs to a newer class […]

KKR & Co. (NYSE:KKR) is set to pay a $250 million civil penalty after the private equity firm allegedly violated the Hart-Cottrell-Rodino Act by withholding and altering documents and failing to make required filings. The HSR Act requires M&A parties...

The U.S. Food and Drug Administration (FDA) on Tuesday approved Abbott Laboratories’ (NYSE:ABT) Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged two and older. The regulatory nod makes the device the first wearable in the U.S. to monitor ketone levels continuously. It also represents the first global system to track blood sugar and ketones simultaneously within a single unit. Clinical Data And De Novo Pathway The agency granted marketing authorization

JNJ's Imaavy wins FDA approval for wAIHA, becoming the first treatment specifically indicated for the rare autoimmune disease.

The Food and Drug Administration cleared a blood test for identifying Alzheimer’s disease symptoms, which was developed by Roche and Eli Lilly.

In August 2026, Regeneron Pharmaceuticals announced that the US FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and flare-ups in adults with fibrodysplasia ossificans progressiva, based on positive Phase 3 OPTIMA trial results. This approval adds a rare-disease monoclonal antibody to Regeneron’s portfolio, reinforcing the company’s focus on specialized, high-complexity immunology therapies. We’ll now examine how Pasatru’s FOP approval, as an ultra-rare...

Apple is changing its fee structure for app developers in the European Union after years of regulatory pressure over its App Store practices.

Apple has agreed to major concessions in Europe to resolve regulatory antitrust disputes, replacing its controversial per-install download fee.

Apple seeks to end a yearslong antitrust dispute over how the tech company manages its devices and App Store that included a $579 million fine.

Bristol-Myers Squibb stock has delivered a 38.1% gain over the past year, while valuation work using a Discounted Cash Flow (DCF) intrinsic value estimate and earnings multiples both currently point to the shares trading at a discount to that estimate. For investors, that combination of strong recent returns and a still supportive valuation framework raises the question of how much margin of safety may remain in the current price. The 38.1% one year return shows that sentiment toward...

Sycamore Capital Management, a franchise of Victory Capital Management, released its Q2 2026 investor letter for “Sycamore Mid Cap Value Equity Strategy”. A copy of the letter can be downloaded here. Sycamore Capital’s Mid Cap Value investment team focuses on a bottom-up approach to identify undervalued businesses with growth potential. In Q2 2026, the strategy […]

Makan Delrahim made the disclosure at Politico’s California Agenda conference, according to Reuters, signaling that Paramount is willing to go beyond internal safeguards to salvage a deal that has become one of the most politically charged media mergers in years. Warner Bros. Discovery is the publicly traded parent of CNN (NASDAQ: WBD), and the merger’s fate directly determines whether Ellison’s Paramount consolidates control over both CBS News and the cable network.

mFLUSIVA is now the first and only mRNA standalone seasonal influenza vaccine on the market, marking a major advancement for the field.

Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J’s MedTech ambitions, but the company is entering a market in which Intuitive Surgical (NASDAQ:ISRG) already has an extensive installed base, established surgeon […]

Firefox developer Mozilla is warning that it could be forced to "exit the browser and browser engine markets" if it can no longer receive payment from Google for distributing its search engine.

Dismissal removes one legal challenge involving compounded alternatives while Novo confronts intensifying commercial competition in obesity treatments.

A Texas judge dismissed claims that the drugmakers illegally blocked access to compounded weight-loss drugs.

Moderna has secured FDA approval for its flu vaccine mFLUSIVA. But does that warrant buying MRNA shares today? Let’s find out!

Moderna (NASDAQ:MRNA) announced on Thursday that the U. S.

The Food and Drug Administration approved Moderna’s mRNA-based flu vaccine for adults ages 50 and older, clearing the first shot of its kind after a review process that nearly collapsed in February. The vaccine, called mFlusiva, uses the same mRNA technology as Moderna’s Covid-19 shots. It could reach pharmacies in time for the coming flu season, which typically starts in the fall.